⭐NAR Breakthrough! ⭐
#RNAtherapeutics show strong promise for #CNSdisorders 🧠. #Preclinical studies reveal that very high doses of #oligonucleotides can cause brief, reversible neuronal activation driven by metal ion interactions 🧪.
Read the full article here: doi.org/10.1093/nar/...
#RNAtherapeutics show strong promise for #CNSdisorders 🧠. #Preclinical studies reveal that very high doses of #oligonucleotides can cause brief, reversible neuronal activation driven by metal ion interactions 🧪.
Read the full article here: doi.org/10.1093/nar/...
February 4, 2026 at 4:34 PM
⭐NAR Breakthrough! ⭐
#RNAtherapeutics show strong promise for #CNSdisorders 🧠. #Preclinical studies reveal that very high doses of #oligonucleotides can cause brief, reversible neuronal activation driven by metal ion interactions 🧪.
Read the full article here: doi.org/10.1093/nar/...
#RNAtherapeutics show strong promise for #CNSdisorders 🧠. #Preclinical studies reveal that very high doses of #oligonucleotides can cause brief, reversible neuronal activation driven by metal ion interactions 🧪.
Read the full article here: doi.org/10.1093/nar/...
#GLP1R agonists show clinical promise in treating more than obesity and diabetes. In Sept 2024, we hosted a workshop exploring the potential for GLP-1 agonists to treat #CNSdisorders like substance use disorders, and more. Access the proceedings here: buff.ly/43fY2Tk
February 28, 2025 at 5:45 PM
#GLP1R agonists show clinical promise in treating more than obesity and diabetes. In Sept 2024, we hosted a workshop exploring the potential for GLP-1 agonists to treat #CNSdisorders like substance use disorders, and more. Access the proceedings here: buff.ly/43fY2Tk
www.linkedin.com/pulse/noema-...
Noema Pharma Raises CHF 130 Million in Series B Extension to Advance Breakthrough CNS Treatments
kstrategyand.com/pharma-news
#NoemaPharma #CNSDisorders #Neuroscience #SeriesBFunding #EQTLifeSciences #Neurotherapeutics #Humanteconomy #Humantec #KStrategyand
Noema Pharma Raises CHF 130 Million in Series B Extension to Advance Breakthrough CNS Treatments
kstrategyand.com/pharma-news
#NoemaPharma #CNSDisorders #Neuroscience #SeriesBFunding #EQTLifeSciences #Neurotherapeutics #Humanteconomy #Humantec #KStrategyand
Noema Pharma Raises CHF 130 Million in Series B Extension to Advance Breakthrough CNS Treatments
Noema Pharma, a clinical-stage biotech company focused on developing innovative treatments for central nervous system (CNS) disorders, has successfully closed an extension of its Series B financing ro...
www.linkedin.com
January 13, 2025 at 9:24 AM
www.linkedin.com/pulse/noema-...
Noema Pharma Raises CHF 130 Million in Series B Extension to Advance Breakthrough CNS Treatments
kstrategyand.com/pharma-news
#NoemaPharma #CNSDisorders #Neuroscience #SeriesBFunding #EQTLifeSciences #Neurotherapeutics #Humanteconomy #Humantec #KStrategyand
Noema Pharma Raises CHF 130 Million in Series B Extension to Advance Breakthrough CNS Treatments
kstrategyand.com/pharma-news
#NoemaPharma #CNSDisorders #Neuroscience #SeriesBFunding #EQTLifeSciences #Neurotherapeutics #Humanteconomy #Humantec #KStrategyand
🔬 From a gut microbiota-derived metabolite to a potential therapeutic approach: this review explores urolithin A and its potential in CNS disorders, alongside the challenges of clinical translation. #UrolithinA #CNSDisorders
🔗 www.mdpi.com/2227-9059/13...
🔗 www.mdpi.com/2227-9059/13...
August 26, 2026 at 12:34 AM
🔬 From a gut microbiota-derived metabolite to a potential therapeutic approach: this review explores urolithin A and its potential in CNS disorders, alongside the challenges of clinical translation. #UrolithinA #CNSDisorders
🔗 www.mdpi.com/2227-9059/13...
🔗 www.mdpi.com/2227-9059/13...
Enveric Biosciences' EB-003 Shows Potential for Broader Neurological Treatment Applications
ainewsbrew.com/article/4791
#EnvericBiosciences #EB003 #BiotechBreakthrough #NeurologicalTreatment #DrugDevelopment #CNSDisorders #MentalHealth #ParkinsonsResearch #MigraineTreatment #NASDAQNews
ainewsbrew.com/article/4791
#EnvericBiosciences #EB003 #BiotechBreakthrough #NeurologicalTreatment #DrugDevelopment #CNSDisorders #MentalHealth #ParkinsonsResearch #MigraineTreatment #NASDAQNews
Enveric Biosciences' EB-003 Shows Potential for Broader Neurological Treatment Applications | AI News Brew
<p>CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on developing novel neuroplastogenic small-molecule therapeutics, has announced new data that expands the pote...
ainewsbrew.com
June 24, 2025 at 3:15 PM
Enveric Biosciences' EB-003 Shows Potential for Broader Neurological Treatment Applications
ainewsbrew.com/article/4791
#EnvericBiosciences #EB003 #BiotechBreakthrough #NeurologicalTreatment #DrugDevelopment #CNSDisorders #MentalHealth #ParkinsonsResearch #MigraineTreatment #NASDAQNews
ainewsbrew.com/article/4791
#EnvericBiosciences #EB003 #BiotechBreakthrough #NeurologicalTreatment #DrugDevelopment #CNSDisorders #MentalHealth #ParkinsonsResearch #MigraineTreatment #NASDAQNews
#AlzheimersDisease #Dementia #neflamapimod #CNSdisorders #biotech #CervoMed #dementiapatients #RewinDLBstudy #dementiawithLewybodies #DLB #ClinicalDementiaRatingSumofBoxes #CDRSB #AlzheimersDiseaseCooperativeStudy #ClinicalGlobalImpressionofChange #CGIC
pharmatimes.com/news/dementi...
pharmatimes.com/news/dementi...
Dementia drug neflamapimod shows positive phase 2b trial results - PharmaTimes
CervoMed's therapy demonstrates significant improvement in patients
pharmatimes.com
March 12, 2025 at 12:02 PM
#mentalhealth #CNSdisorders #Neuraxpharm #Pharmathen #longactinginjectabletherapies #LATT #psychiatry #LATTprogram #shortactingdosageforms #prescribers #patientcompliance #LAI #LAIproducts #CNSproducts #CNSpatients #establishedtherapies #patientchoice
pf-media.co.uk/news/neuraxp...
pf-media.co.uk/news/neuraxp...
Neuraxpharm and Pharmathen partner to develop long-acting injectable therapies - Pf Media
Neuraxpharm and Pharmathen have announced a strategic alliance to co-develop new long-acting injectable therapies.
pf-media.co.uk
December 13, 2024 at 11:44 AM
🌟 Accelerating Drug Discovery in CNS Disorders 🌟
Discover how SynapCell can revolutionize and accelerate your drug development process. Let's push the boundaries of neuroscience together!
#DrugDiscovery #CNSdisorders #PreclinicalResearch
Discover how SynapCell can revolutionize and accelerate your drug development process. Let's push the boundaries of neuroscience together!
#DrugDiscovery #CNSdisorders #PreclinicalResearch
February 25, 2025 at 3:16 PM
🌟 Accelerating Drug Discovery in CNS Disorders 🌟
Discover how SynapCell can revolutionize and accelerate your drug development process. Let's push the boundaries of neuroscience together!
#DrugDiscovery #CNSdisorders #PreclinicalResearch
Discover how SynapCell can revolutionize and accelerate your drug development process. Let's push the boundaries of neuroscience together!
#DrugDiscovery #CNSdisorders #PreclinicalResearch
Join @NASEM_Health’s #NeuroForum on March 13-14 for a workshop exploring how psychiatry, pediatric neurology, and neurodevelopmental disorders are progressing multimodal biomarker generation. Register: http://ow.ly/zSEF50MBq2f #CNSDisorders
ow.ly
ow.ly
ow.ly
February 22, 2026 at 2:47 AM
Join @NASEM_Health’s #NeuroForum on March 13-14 for a workshop exploring how psychiatry, pediatric neurology, and neurodevelopmental disorders are progressing multimodal biomarker generation. Register: http://ow.ly/zSEF50MBq2f #CNSDisorders
BioSymetrics is at BIO talking with partners about how our platform supports target discovery and clinical trial enrichment in CNS disorders. We see CNS as a strong proof point for a broader development strategy. #BIO2026 #CNSDisorders #DrugDiscovery
June 24, 2026 at 12:10 AM
BioSymetrics is at BIO talking with partners about how our platform supports target discovery and clinical trial enrichment in CNS disorders. We see CNS as a strong proof point for a broader development strategy. #BIO2026 #CNSDisorders #DrugDiscovery